nodes	percent_of_prediction	percent_of_DWPC	metapath
Vapreotide—SSTR5—Peptide GPCRs—MC1R—skin cancer	0.0602	0.0602	CbGpPWpGaD
Vapreotide—SSTR2—Peptide GPCRs—MC1R—skin cancer	0.0555	0.0555	CbGpPWpGaD
Vapreotide—TACR1—Peptide GPCRs—MC1R—skin cancer	0.0437	0.0437	CbGpPWpGaD
Vapreotide—SSTR2—GPCRs, Other—SMO—skin cancer	0.0318	0.0318	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—CSPG4—skin cancer	0.0315	0.0315	CbGpPWpGaD
Vapreotide—SSTR5—Peptide ligand-binding receptors—MC1R—skin cancer	0.0283	0.0283	CbGpPWpGaD
Vapreotide—SSTR2—Peptide ligand-binding receptors—MC1R—skin cancer	0.0261	0.0261	CbGpPWpGaD
Vapreotide—SSTR5—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.0221	0.0221	CbGpPWpGaD
Vapreotide—TACR1—Peptide ligand-binding receptors—MC1R—skin cancer	0.0206	0.0206	CbGpPWpGaD
Vapreotide—SSTR2—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.0204	0.0204	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—PTCH2—skin cancer	0.02	0.02	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.019	0.019	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—PTCH2—skin cancer	0.0184	0.0184	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.0175	0.0175	CbGpPWpGaD
Vapreotide—SSTR5—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.0146	0.0146	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—PTCH2—skin cancer	0.0145	0.0145	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—MC1R—skin cancer	0.0145	0.0145	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.0138	0.0138	CbGpPWpGaD
Vapreotide—SSTR2—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.0134	0.0134	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—MC1R—skin cancer	0.0133	0.0133	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.0125	0.0125	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—RHOU—skin cancer	0.0124	0.0124	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.0115	0.0115	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—RHOU—skin cancer	0.0115	0.0115	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—MC1R—skin cancer	0.0105	0.0105	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—CDK4—skin cancer	0.0104	0.0104	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—SHH—skin cancer	0.0103	0.0103	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—PTCH2—skin cancer	0.0103	0.0103	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—SMO—skin cancer	0.00976	0.00976	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—PTCH1—skin cancer	0.00976	0.00976	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—PTGER4—skin cancer	0.0095	0.0095	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—SHH—skin cancer	0.0095	0.0095	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—PTCH2—skin cancer	0.00947	0.00947	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00907	0.00907	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—RHOU—skin cancer	0.00901	0.00901	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—PTCH1—skin cancer	0.00901	0.00901	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—SMO—skin cancer	0.00901	0.00901	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—PTGER4—skin cancer	0.00877	0.00877	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—MC1R—skin cancer	0.00817	0.00817	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—MC1R—skin cancer	0.00754	0.00754	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—SHH—skin cancer	0.00748	0.00748	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—PTGS2—skin cancer	0.00747	0.00747	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—PTCH2—skin cancer	0.00745	0.00745	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—MC1R—skin cancer	0.00742	0.00742	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—SMO—skin cancer	0.00709	0.00709	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—PTCH1—skin cancer	0.00709	0.00709	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—PTGER4—skin cancer	0.0069	0.0069	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—MC1R—skin cancer	0.00684	0.00684	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—PTCH2—skin cancer	0.00606	0.00606	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—MC1R—skin cancer	0.00593	0.00593	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—PTCH2—skin cancer	0.00559	0.00559	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—MC1R—skin cancer	0.00539	0.00539	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—PTGER4—skin cancer	0.00537	0.00537	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—SHH—skin cancer	0.00528	0.00528	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—SMO—skin cancer	0.00501	0.00501	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—PTCH1—skin cancer	0.00501	0.00501	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—PTGER4—skin cancer	0.00496	0.00496	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—SHH—skin cancer	0.00488	0.00488	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—PTGER4—skin cancer	0.00488	0.00488	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—PTCH1—skin cancer	0.00462	0.00462	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—SMO—skin cancer	0.00462	0.00462	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—GLI2—skin cancer	0.00459	0.00459	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—PTGER4—skin cancer	0.0045	0.0045	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—TP53—skin cancer	0.00444	0.00444	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—PTCH2—skin cancer	0.0044	0.0044	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—MC1R—skin cancer	0.00438	0.00438	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—GLI1—skin cancer	0.00432	0.00432	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—GLI2—skin cancer	0.00424	0.00424	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—IL6—skin cancer	0.00413	0.00413	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—SUFU—skin cancer	0.00409	0.00409	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—IL6—skin cancer	0.00407	0.00407	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—MC1R—skin cancer	0.00404	0.00404	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—GLI1—skin cancer	0.00398	0.00398	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—PTGER4—skin cancer	0.0039	0.0039	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—SHH—skin cancer	0.00384	0.00384	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—SUFU—skin cancer	0.00378	0.00378	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—SMO—skin cancer	0.00364	0.00364	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—PTCH1—skin cancer	0.00364	0.00364	CbGpPWpGaD
Vapreotide—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.0036	0.0036	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—PTGER4—skin cancer	0.00354	0.00354	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—GLI2—skin cancer	0.00334	0.00334	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—IL6—skin cancer	0.00325	0.00325	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—MC1R—skin cancer	0.00318	0.00318	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—GLI1—skin cancer	0.00314	0.00314	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—SHH—skin cancer	0.00312	0.00312	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—RASA1—skin cancer	0.0031	0.0031	CbGpPWpGaD
Vapreotide—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.00309	0.00309	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—SUFU—skin cancer	0.00297	0.00297	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—PTCH1—skin cancer	0.00296	0.00296	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—SMO—skin cancer	0.00296	0.00296	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—PTGER4—skin cancer	0.00288	0.00288	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—SHH—skin cancer	0.00288	0.00288	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—RASA1—skin cancer	0.00286	0.00286	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—SMO—skin cancer	0.00273	0.00273	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—PTCH1—skin cancer	0.00273	0.00273	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—PTGER4—skin cancer	0.00266	0.00266	CbGpPWpGaD
Vapreotide—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.00263	0.00263	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—FOXO4—skin cancer	0.00254	0.00254	CbGpPWpGaD
Vapreotide—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.00252	0.00252	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—FOXO4—skin cancer	0.00235	0.00235	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—SHH—skin cancer	0.00227	0.00227	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—RASA1—skin cancer	0.00225	0.00225	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—SMO—skin cancer	0.00215	0.00215	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—PTCH1—skin cancer	0.00215	0.00215	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—PTGER4—skin cancer	0.00209	0.00209	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—FOXO4—skin cancer	0.00185	0.00185	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—TERT—skin cancer	0.0017	0.0017	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—TERT—skin cancer	0.00157	0.00157	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—NRAS—skin cancer	0.00143	0.00143	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—BRAF—skin cancer	0.00135	0.00135	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—NRAS—skin cancer	0.00132	0.00132	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—BRAF—skin cancer	0.00124	0.00124	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—TERT—skin cancer	0.00123	0.00123	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—KRAS—skin cancer	0.00123	0.00123	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—KRAS—skin cancer	0.00114	0.00114	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—HRAS—skin cancer	0.00105	0.00105	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—NRAS—skin cancer	0.00104	0.00104	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—IL6—skin cancer	0.001	0.001	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—BRAF—skin cancer	0.000978	0.000978	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—HRAS—skin cancer	0.000967	0.000967	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—IL6—skin cancer	0.000925	0.000925	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—KRAS—skin cancer	0.000895	0.000895	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—NRAS—skin cancer	0.000846	0.000846	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—NRAS—skin cancer	0.000781	0.000781	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—HRAS—skin cancer	0.000761	0.000761	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—IL6—skin cancer	0.000728	0.000728	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—KRAS—skin cancer	0.000728	0.000728	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—KRAS—skin cancer	0.000672	0.000672	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—TP53—skin cancer	0.000647	0.000647	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—HRAS—skin cancer	0.000619	0.000619	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—NRAS—skin cancer	0.000615	0.000615	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—TP53—skin cancer	0.000597	0.000597	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—IL6—skin cancer	0.000592	0.000592	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—HRAS—skin cancer	0.000571	0.000571	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—IL6—skin cancer	0.000547	0.000547	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—KRAS—skin cancer	0.000529	0.000529	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—TP53—skin cancer	0.00047	0.00047	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—HRAS—skin cancer	0.00045	0.00045	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—IL6—skin cancer	0.00043	0.00043	CbGpPWpGaD
